Wulf, Gerburg M.

PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer

Pantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M. K., Pinto, J., Castrillon, J. A., et al. (2019) · Cancer Discovery

PARP inhibition in cancer therapyCancer Immunotherapy and Biomarkers

Cited by 743

The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein

Lu, P.-J., Wulf, G., Zhou, X. Z., Davies, P., & Lu, K. P. (1999) · Nature

Alzheimer's disease research and treatmentsSignaling Pathways in Disease

Cited by 721

PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells

Israelsen, W. J., Dayton, T. L., Davidson, S. M., Fiske, B. P., Hosios, A. M., Bellinger, G., Li, J., Yu, Y., Sasaki, M., Horner, J. W., et al. (2013) · Cell

Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer

Cited by 549

The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-β production

Pastorino, L., Sun, A., Lu, P.-J., Zhou, X. Z., Balastik, M., Finn, G., Wulf, G., Lim, J., Li, S.-H., Li, X., et al. (2006) · Nature

Alzheimer's disease research and treatmentsSignaling Pathways in Disease

Cited by 487

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial

Konstantinopoulos, P. A., Barry, W. T., Birrer, M., Westin, S. N., Cadoo, K. A., Shapiro, G. I., Mayer, E. L., O'Cearbhaill, R. E., Coleman, R. L., Kochupurakkal, B., et al. (2019) · The Lancet Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 263

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy

Morrow, P. K., Wulf, G. M., Ensor, J., Booser, D. J., Moore, J. A., Flores, P. R., Xiong, Y., Zhang, S., Krop, I. E., Winer, E. P., et al. (2011) · Journal of Clinical Oncology

HER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 209

Inhibition of hematopoiesis by competitive binding of transcription factor PU.1

Voso, M. T., Burn, T. C., Wulf, G., Lim, B., Leone, G., & Tenen, D. G. (1994) · Proceedings of the National Academy of Sciences

Hematopoietic Stem Cell TransplantationGenomics and Chromatin Dynamics

Cited by 141

Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics

Liu, J. F., Palakurthi, S., Zeng, Q., Zhou, S., Ivanova, E., Huang, W., Zervantonakis, I. K., Selfors, L. M., Shen, Y., Pritchard, C. C., et al. (2017) · Clinical Cancer Research

Ovarian cancer diagnosis and treatmentBRCA gene mutations in cancer

Cited by 127

Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion

Juvekar, A., Hu, H., Yadegarynia, S., Lyssiotis, C. A., Ullas, S., Lien, E. C., Bellinger, G., Son, J., Hok, R. C., Seth, P., et al. (2016) · Proceedings of the National Academy of Sciences

PARP inhibition in cancer therapyPI3K/AKT/mTOR signaling in cancer

Cited by 93

TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.

Vinayak, S., Tolaney, S. M., Schwartzberg, L. S., Mita, M. M., McCann, G. A.-L., Tan, A. R., Wahner Hendrickson, A. E., Forero-Torres, A., Anders, C. K., Wulf, G. M., et al. (2018) · Journal of Clinical Oncology

PARP inhibition in cancer therapyBreast Cancer Treatment Studies

Cited by 77

Targeting transcription factors through an IMiD independent zinc finger domain

Liu, B. H., Liu, M., Radhakrishnan, S., Dai, M.-Y., Jaladanki, C. K., Gao, C., Tang, J. P., Kumari, K., Go, M. L., Vu, K. A. L., et al. (2025) · EMBO Molecular Medicine

Protein Degradation and InhibitorsChromatin Remodeling and Cancer

Cited by 8